These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 24499497)

  • 1. Libertas: rationale and study design of a multicentre, Phase II, double-blind, randomised, placebo-controlled investigation to evaluate the efficacy, safety and tolerability of locally applied NRL001 in patients with faecal incontinence.
    Siproudhis L; Jones D; Shing RN; Walker D; Scholefield JH;
    Colorectal Dis; 2014 Mar; 16 Suppl 1():59-66. PubMed ID: 24499497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind, placebo-controlled, randomised, parallel-group, dose-escalating, repeat dose study in healthy volunteers to evaluate the safety, tolerability, pharmacodynamic effects and pharmacokinetics of the once daily rectal application of NRL001 suppositories for 14 days.
    Bell D; Duffin A; Jacobs A; Pediconi C; Gruss HJ
    Colorectal Dis; 2014 Mar; 16 Suppl 1():36-50. PubMed ID: 24499495
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Libertas: a phase II placebo-controlled study of NRL001 in patients with faecal incontinence showed an unexpected and sustained placebo response.
    Siproudhis L; Graf W; Emmanuel A; Walker D; Shing RN; Pediconi C; Pilot J; Wexner S; Scholefield J
    Int J Colorectal Dis; 2016 Jun; 31(6):1205-16. PubMed ID: 27075314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomised, controlled, crossover study to investigate the pharmacodynamics, pharmacokinetics and safety of 1R,2S-methoxamine hydrochloride (NRL001) in healthy elderly subjects.
    Bell D; Duffin A; Gruss HJ; Pediconi C; Jacobs A
    Colorectal Dis; 2014 Mar; 16 Suppl 1():27-35. PubMed ID: 24499494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomised, controlled, crossover study to investigate the safety and response of 1R,2S-methoxamine hydrochloride (NRL001) on anal function in healthy volunteers.
    Simpson JA; Bush D; Gruss HJ; Jacobs A; Pediconi C; Scholefield JH
    Colorectal Dis; 2014 Mar; 16 Suppl 1():5-15. PubMed ID: 24499492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomised clinical trial: study of escalating doses of NRL001 given in rectal suppositories of different weights.
    Bell D; Pediconi C; Jacobs A
    Colorectal Dis; 2014 Mar; 16 Suppl 1():16-26. PubMed ID: 24499493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy and safety of PSD503 (phenylephrine 20%, w/w) for topical application in women with stress urinary incontinence. A phase II, multicentre, double-blind, placebo controlled, 2-way cross over study.
    Robinson D; Abrams P; Cardozo L; Ellis-Jones J; Heath P; Wyllie M
    Eur J Obstet Gynecol Reprod Biol; 2011 Dec; 159(2):457-60. PubMed ID: 21831512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meta-analysis for cardiovascular effects of NRL001 after rectal application in healthy volunteers.
    Gruss HJ; Pediconi C; Jacobs A
    Colorectal Dis; 2014 Mar; 16 Suppl 1():51-8. PubMed ID: 24499496
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of mirabegron, a β(3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial.
    Khullar V; Amarenco G; Angulo JC; Cambronero J; Høye K; Milsom I; Radziszewski P; Rechberger T; Boerrigter P; Drogendijk T; Wooning M; Chapple C
    Eur Urol; 2013 Feb; 63(2):283-95. PubMed ID: 23182126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase III, randomized, double-blind, parallel-group, placebo-controlled, multicentre study to assess the efficacy and safety of the β₃ adrenoceptor agonist, mirabegron, in patients with symptoms of overactive bladder.
    Herschorn S; Barkin J; Castro-Diaz D; Frankel JM; Espuna-Pons M; Gousse AE; Stölzel M; Martin N; Gunther A; Van Kerrebroeck P
    Urology; 2013 Aug; 82(2):313-20. PubMed ID: 23769122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
    Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
    Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrarectal injections of botulinum toxin versus placebo for the treatment of urge faecal incontinence in adults (FI-Toxin): a double-blind, multicentre, randomised, controlled phase 3 study.
    Leroi AM; Queralto M; Zerbib F; Siproudhis L; Vitton V; Amarenco G; Etienney I; Mion F; Bridoux V; Philip J; Brochard C; Damon H; Lacroix E; Gillibert A; Gourcerol G
    Lancet Gastroenterol Hepatol; 2024 Feb; 9(2):147-158. PubMed ID: 38128556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized double-blind placebo-controlled multicentre study to explore the efficacy and safety of tamsulosin and tolterodine in women with overactive bladder syndrome.
    Robinson D; Cardozo L; Terpstra G; Bolodeoku J;
    BJU Int; 2007 Oct; 100(4):840-5. PubMed ID: 17822465
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study.
    Moon DE; Lee DI; Lee SC; Song SO; Yoon DM; Yoon MH; Kim HK; Lee YW; Kim C; Lee PB
    Clin Ther; 2010 Dec; 32(14):2370-85. PubMed ID: 21353106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic detrusor overactivity: a randomised, double-blind, placebo-controlled trial.
    Cruz F; Herschorn S; Aliotta P; Brin M; Thompson C; Lam W; Daniell G; Heesakkers J; Haag-Molkenteller C
    Eur Urol; 2011 Oct; 60(4):742-50. PubMed ID: 21798658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation of dose titration with darifenacin, an M3-selective receptor antagonist.
    Steers W; Corcos J; Foote J; Kralidis G
    BJU Int; 2005 Mar; 95(4):580-6. PubMed ID: 15705084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder.
    Chapple C; Steers W; Norton P; Millard R; Kralidis G; Glavind K; Abrams P
    BJU Int; 2005 May; 95(7):993-1001. PubMed ID: 15839920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation--a 12-week, randomized, double-blind, placebo-controlled study.
    Quigley EM; Vandeplassche L; Kerstens R; Ausma J
    Aliment Pharmacol Ther; 2009 Feb; 29(3):315-28. PubMed ID: 19035970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New treatment for faecal incontinence using zinc-aluminium ointment: a double-blind randomized trial.
    Pinedo G; Zarate AJ; Inostroza G; Meneses X; Falloux E; Molina O; Molina ME; Bellolio F; Zúñiga A
    Colorectal Dis; 2012 May; 14(5):596-8. PubMed ID: 21781231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term open-label solifenacin treatment associated with persistence with therapy in patients with overactive bladder syndrome.
    Haab F; Cardozo L; Chapple C; Ridder AM;
    Eur Urol; 2005 Mar; 47(3):376-84. PubMed ID: 15716204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.